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The past decades have seen a dramatic increase in obesity and type 2 
diabetes mellitus (DM) in all age-groups (Amiel et al. 1986, Ginter and Simko 
2012, Pinhas-Hamiel and Zeitler 2005), and the metabolic pathways 
responsible for its development, are the target of ongoing research. The brain 
plays a central role in whole body energy homeostasis, integrating neuronal 
and humoral signals from the periphery. Evaluating the pathways involved will 
therefore be the basis to further our understanding of obesity and diabetes. 
The present work tries to further assess the role of the brain, in particular the 
role of the hypothalamus, in regulating glucose and lipid metabolism, by using 
targeted metabolomic profiling. First, I will describe the basic principles of DM 
and its epidemiological importance, before explaining the rationale for 
conducting these studies. 
 
1.1 Diabetes mellitus 
 
Characterized by chronic hyperglycemia, DM is a disorder of either impaired 
insulin production or sensitivity and therefore affects whole body metabolism. 
This not only leads to secondary damages, such as microangiopathy or 
peripheral neuropathy, but also holds the danger of diabetic ketoacidosis and 
coma (Berry et al. 2012, de Boer et al. 2011, Felig 1974, Holman et al. 2008, 
Mauer et al. 2009, Patel et al. 2008, Tesfaye et al. 2005).  
 
According to the World Health Organization (WHO), DM is diagnosed if the 
patient shows classical symptoms, like polyuria, polydipsia, weight loss, 
fatigue, and his fasting plasma glucose concentration is ≥7 mmol/L (126 
mg/dL) or ≥11.1 mmol/L (200 mg/dL), 2 hours after a 75g glucose drink.  
In addition to impairing fasting glucose (IFG), intermediate states impair 
glucose tolerance (IGT) and frequently lead to diabetes mellitus type 2 (DM2). 
IFG is defined by the American Diabetes Association (ADA) as fasting plasma 
glucose ≥5.6 mmol/L (100 mg/dL) and <7 mmol/L (126 mg/dL), whereas the 
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intermediate levels of IGT require plasma glucose levels to be ≥7.8 mmol/L 
(140 mg/dL) and <11.1 mmol/L (200 mg/dL) 2 hours after a 75g glucose drink. 
1.1.1 Classification of diabetes mellitus 
 
Type 1 diabetes 
Diabetes mellitus type 1 (DM1) is characterized by absolute insulin deficiency 
usually due to autoimmune destruction of the beta cells of the pancreas. This 
form was formerly known as insulin-dependent diabetes mellitus (IDDM) in 
comparison to non-insulin dependent diabetes mellitus (NIDDM). DM1 mostly 
develops in children and adolescents that require insulin injections for survival 
and patients are more susceptible to ketoacidosis or diabetic coma. 
  
Type 2 diabetes 
This type of diabetes strongly correlates with obesity, insufficient physical 
activity, unhealthy diet and includes 90% of the patients with DM. It usually 
develops in adults showing few or no symptoms for years, due to 
compensatory insulin production by the beta-islet cells. Insulin resistance as 
well as impaired glucose tolerance follows, resulting in increased fasting 
plasma glucose, which results in development of an intermediate stage. 
Generally, there is a good chance of resolving DM2 in the intermediate stage, 




Using the above mentioned guidelines, the age-standardized prevalence of 
DM was about 9.5% in 2008, i.e. about 346 million people worldwide met the 
criteria for DM (Danaei et al. 2011). In Germany, the population that were 
being treated for DM rose from 5.9% in 1998 to 8.9% in 2007 (Rathmann et 
al. 2009). This increase was mainly caused by the early onset of obesity in 
adolescents and children as well as the overall increase in life expectancy. 
Nonetheless DM remains as a global epidemic and public awareness should 
be increased. The consumption of high sugar, high fat food and a sedentary 




1.2 Hypothalamic leptin and insulin signaling 
Hyperinsulinemia and hyperleptinemia are hallmarks of insulin resistance and 
obesity, respectively. Hepatic insulin resistance develops early in DM2 and is 
at least in part regulated by brain signaling (Ono et al. 2008). While insulin 
has numerous functions as a systemic hormone, leptin’s role in energy 
metabolism was first discovered through its actions in the central nervous 
system and its ability to reduce food intake in a rodent model (Campfield et al. 
1995, Halaas et al. 1995). The hypothalamus plays an integral role in nutrient 
sensing and the regulation of glucose homeostasis as well as obesity (Jung 
and Kim 2013, Lam et al. 2010, Lam et al. 2005, Pocai et al. 2005c, Pocai et 
al. 2006, Toda et al. 2013). In rats for example, hypothalamic sensing of intact 
free fatty acid (FFA) prevents an exacerbated increase in hepatic glucose 
production due to elevated plasma FFA levels (Lam et al. 2005). 
 
Since energy homeostasis is not only determined by caloric intake, but also 
through regulation of nutrient partitioning, we probed the role of leptin and 
insulin signaling in hypothalamic control of whole body glucose and lipid 
metabolism (Schwartz et al. 2000, Schwartz and Porte 2005). Within the 
hypothalamus, several neuronal populations in the mediobasal hypothalamus 
(MBH), regulate glucose metabolism (Buettner and Camacho 2008, Obici et 
al. 2002, Wu et al. 2009) and express insulin as well as leptin receptors 
(Baskin et al. 1999, Pansky and Hatfield 1978).  
 
Produced by adipocytes, leptin has a high impact on metabolism as a 
hormone acting through the central nervous system (CNS) (Campfield et al. 
1995, Cohen et al. 2001, Halaas et al. 1995, Montague et al. 1997, 
Pelleymounter et al. 1995, Weigle et al. 1995, Zhang et al. 2010). Part of its 
regulatory functions in glucose metabolism can be explained through an 
increase in hypothalamic insulin sensitivity (Koch et al. 2010), while intact 
signal transducer and activator of transcription 3 (STAT3) signaling is crucial 
for its ability to reduce food intake and maintenance of glucose homeostasis 
(Buettner et al. 2006). Administered into the MBH it is able to suppress de 
novo lipogenesis as well as free fatty acid (FFA) uptake in white adipose 
tissue (WAT) (Buettner et al. 2008) through increase in sympathetic activity, 
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independently from STAT3 signaling. Acutely administered into the third 
ventricle of Sprague-Dawley (SD) rats, leptin leads to a decrease in hepatic 
glycogenolysis and an increase in gluconeogenesis when circulating insulin is 
kept constant using pancreatic clamps. The increase in gluconeogenesis is 
due to the effect of melanocyte-stimulating hormone (MSH) signaling in the 
brain, as the effect could be blunted by co-administration of a MSH-inhibitor 
(Gutierrez-Juarez et al. 2004). While this model emphasized the role of leptin 
signaling in the whole brain, we have tried to focus only on hypothalamic 
signaling by direct administration of leptin into the MBH under pancreatic 
clamp conditions. 
 
Centrally administered insulin on the other hand reduces food intake via 
hypothalamic signaling (Air et al. 2002, Chavez et al. 1995, Woods et al. 
1979) and plays an important role in whole body glucose and lipid metabolism 
(Bruning et al. 2000, Lindtner et al. 2013, Obici et al. 2002, Scherer et al. 
2012), as it suppresses hepatic glucose production (Pocai et al. 2005a) and 
leads to an increase of de novo lipogenesis in WAT.  
 
Since both, insulin and leptin, have numerous effects on energy metabolism 
through brain signaling, we established an unbiased, non-hypothesis-driven, 
approach to analyse metabolic pathways using different isotope-tracers and 
mass spectrometry for targeted metabolomics. These techniques helped us in 
building hypotheses and in further studying metabolic pathways possibly 
involved in the pathogenesis of DM. To eliminate fluctuations in plasma 
glucose and hormone levels, which may be caused due to the effect of central 
leptin and insulin on the endocrine pancreas, we combined stereotaxic 
infusions in the MBH with euglycemic clamp protocols. This protocol further 
allowed us to determine metabolite fluxes through tracer-dilution studies. 
Either radioactive or non-radioactive isotope-tracer dilution techniques using 
glucose, L-leucine and glycerol served the purpose of determining 
endogenous glucose production/uptake, proteolysis and lipolysis in vivo 
during the pancreatic clamps.   
 A metabolomic approach, such as acylcarnitine measurement, enabled us to 
measure the metabolite flux through mitochondrial membranes and point out 
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the origin of the signal based on the acylcarnitines chain length (Koves et al. 
2008). Via measurement of other metabolites such as amino acids, it was 
possible to investigate earlier observations that had implied an association 
between DM and amino acid metabolism (Felig et al. 1969, Krebs et al. 2002, 
Lu et al. 2013b, Michaliszyn et al. 2012). 
Since mass spectrometry can analyse levels of metabolites this approach was 
used in particular, to study pathways directly involved in nutrient partitioning, 
metabolite breakdown and synthesis.  
 
The TCA cycle plays an important role in energy metabolism (Koubaa et al. 
2013), having versatile sources involving glucose, triglycerides and protein. In 
addition to plasma samples, liver tissue was suitable to analyze biochemical 
pathways, as it is a major organ of metabolism involved in breakdown, 
distribution and genesis of different kinds of energy metabolites.  This study 
therefore focuses on the mechanisms by which central leptin and insulin 
affect hepatic downstream pathways including fatty acid synthesis, β-
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2. Material and methods 
 
2.1 Experimental approach 
 
2.1.1 Administration of hypthalamic Leptin and insulin and 
measurement of systemic metabolites 
Our studies were performed in 10 – 12 week old male Sprague Dawley rats. 
Five groups of animals (n=4-7 for each time point and experiment) were 
studied. One week prior to the experiments the rats had stereotaxic cannulae 
implanted into their MBH and after about 5 days of recovery, they received an 
intra-venous and an intra-arterial catheter through a second surgery.  
During the course of the experiment we sampled 100-500 µL blood every 15 
minutes to determine plasma glucose levels. To control glucose 
concentrations, a variable infusion of 25% glucose solution was used to clamp 
the plasma concentration at basal (~100 - 130 ml/dl) levels. Animals that 
received MBH insulin (Humulin R, Lilly), leptin (Sigma-Aldrich, St. Louis, MO) 
or suitable vehicle (aCSF, Harvard Apparatus, Holliston, MA) received 
primed-continuous intravenous (IV) infusions of non-radioactive [2H-5]–
Glycerol (1 µmol/min*kg-1), (Isotec Miamisburg, OH) and L-Leucine [5,5,5-D3] 
(1 µmol*min-1*kg-1) (Cambridge Isotope Laboratories, Inc., Andover, MA) 
from time t = -120 min followed by a 4 hr pancreatic euglycemic clamp which 
started at t=0. In addition to non-radioactive tracer, we repeated MBH aCSF 
and MBH leptin clamps using radioactive tracers to re-evaluate the impact of 
MBH leptin signaling on glucose metabolism. A prime-continuous infusion 
consisting of a 20 µ Ci bolus followed by a 0.5 µCi/min  infusion of [3-3H]-
glucose (Perkinelmer, Waltham, MA) and [2H-5]–Glycerol (40 µmol/kg bolus, 
followed by a 1 µmol/min*kg-1 infusion, Isotec Miamisburg, OH) was initiated 
and maintained throughout the study. Non-radioactive tracers were used to 
avoid possible malfunctioning of the mass-spectrometer used for metabolomic 
analysis, which could arise from interactions with radioactive substances.  
Proposed study protocols and dosages were based on previously published 
protocols (Buettner et al. 2008, Carvalheira et al. 2003, Roman et al. 2005): 
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A)  6 hours MBH vehicle (0.18 µl/hr per side) + 4 hours euglycemic (100 - 
130 mg/dl) pancreatic/insulin (1 mU/kg.min) clamp.  
B)  6 hours MBH leptin (0.18 µl/hr per side) (200 ng/side) + 4 hours 
euglycemic (100 - 130 mg/dl) pancreatic/insulin (1 mU/kg.min) clamp.  
C)  6 hours MBH insulin (0.18 µl/hr per side) (2 µU/side) + 4 hours 
euglycemic (100 - 130 mg/dl) pancreatic/insulin (1 mU/kg.min) clamp.  
 
All animal protocols were approved by the The Institutional Animal Care and 
Use Committee of The Mount Sinai School of Medicine (Protocol number: 
LA09-00174).  Experiments were performed in male SD rats (Charles River 
Breeding Laboratories, Wilmington, MA). Rats were on a standard rodent diet 
(Rodent Diet 5001, LabDiet, St. Louis, MO) and housed individually in 
separate cages in a temperature- and light- controlled facility (21°C, 12-hour 
light-dark cycle). At the end of the experiment the rats were anesthetized with 
ketamine and then decapitated. We injected food dye into the cannulae to 
confirm their correct placement. Immediately after death of the rats the organs 
were promptly harvested, clamp frozen in liquid nitrogen (T.W. Smith, 
Brooklyn, NY) and stored until further analysis at -80°C. In order to analyze 
the samples using metabolomics (realized by the Stedman Labarotories, 





Rats were injected with approximately 300 µL intraperitoneal (IP) (100 µL 
/100g bodyweight) of ketamine + xylazine mix (200 µL ketamine HCL 
(100mg/ml) + 100 µL Xylazine (20mg/ml) (obtained from and controlled by the 
Center for Comparative Medicine and Surgery of Mount Sinai School Of 
Medicine (CCMS)) with a hypodermic 26G Needle and 1mL Syringe (both BD, 
Franklin Lakes, NJ). To ensure surgical anesthesia, respiratory rate was 
monitored continuously and loss of withdrawal reflex was checked initially by 
pinching the rat’s foot, and throughout the surgery if in doubt of surgical 
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anesthesia (Alves et al. 2010). In case of initially inadequate anesthesia, rats 
were injected IP with 1/3 of the initial dose into the contralateral side of the 
abdomen, while loss of sedation or analgesia during surgery was usually 
counteracted by isoflurane inhalation (2-3%, 100 – 200 mL/min gas flow), 
using a high precision vaporizer system (V3000PK, Parkland Scientific, Coral 
Springs, FL). When fully anesthetized, the surgical area was shaved using an 
animal clipper (Sunbeam-Oster Co., Inc., Fort Lauderdale, FL) and Puralube 
Eye-Lubricant was evenly spread in the inferior eyelid to prevent corneal 
defects (Dechra Veterinary Products, Overland Park, KS). The surgical area 
was then disinfected three times using betadine scrub once followed by 
alcohol swabs twice. 
 
Implantation of Double cannulae into the MBH  
Using a sterile surgical blade an incision was made on the scalp to expose 
the skull. The rat was then fitted in a stereotactic frame (Stoelting Co., Wood 
Dale, IL). Measuring the depth of the bregma and lambda we allowed a 
difference range of 0.01mm. 3 small, 1mm diameter holes were drilled using a 
sterile hand held 1mm long drill bit in a triangle pattern spanning the 
bregmoidal suture of the dorsal skull surface. 1mm diameter sterile stainless 
steel skull screws were implanted in each hole. Stereotactic coordinates were 
selected according to the Paxinos Rat Brain Atlas (Paxinos and Watson 
1998). We then implanted a 26–gauge dual guide cannula system for MBH 
(PlasticsOne, Roanoke, VA). The coordinates used for the MBH were 3.3mm 
posterior from the bregma, 0.4mm bilateral from midline and 9.6mm below the 
surface of the skull. Guide cannulas were blocked using dummy cannulas 
(PlasticsOne, Roanoke, VA) until the day of the experiment. The implant was 
secured to the skull with Loctite 454 Instant Adhesive and Caulk Grip dental 
cement, the skin was closed over the implant using wound clips. If any 
bleeding occurred throughout this procedure it was controlled with sterile 
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Implantation of double catheters  
A longitudinal cut of approximately 2cm was made from the right jugular vein 
towards the contralateral jugular vein using fine scissors (all surgical 
instruments were purchased from Fine Science Tools (USA), Inc., Foster City, 
CA). The jugular vein was located, dissected, adherent tissue removed using 
forceps (Moria Iris Forceps, serrated, curved) and ligated off the cranial end of 
the jugular vein using 6/0 braided silk suture (Ethicon, Somerville, NJ). Before 
cutting the suture the ends of the vein were used to cut a small hole at a 
tangential angle. After successfully placing the jugular catheter (Polyurethane 
Catheter, custom made by Instech Laboratories, Inc., Plymouth Meeting, PA) 
prefilled with heparinized-saline (200 U/mL), placement was ensured through 
the ease of pulling back blood into the catheter tip. Having ensured correct 
placement, the vein containing the catheter was sutured and flushed with 
approximately 0.1ml heparinized-saline and the catheter was blocked with a 
stainless steel catheter plug (Instech Laboratories). The carotid artery was 
then located and dissected in the same manner, using a bullfrog clamp before 
cutting the artery to avoid blood loss. After both catheters were placed, a 
small cut was made of about 3-5 mm in the rear neck and the catheters were 
subcutaneously guided using a Hemostat (Ultra Fine Curved). A single 
continuous suture closed the wound (5/0 Prolene, Ethicon). The ends of the 
catheters were taped together to avoid destruction by biting and scratching. 
All surgical instruments were steam-sterilized daily and bead-sterilized before 
each surgery following the first. 
 
2.1.3 Post-operative care 
Animals were placed on a heat pad (~39°C) under constant observation until 
full recovery of consciousness. Rats were subcutaneously injected with 0.01 - 
0.05mg/kg Buprenorphine (CCMS) bi-daily on 3 consecutive days after 
surgery and checked for bleeding, infections and excessive weight loss 
(>20% bodyweight) or general signs of sickness. If anything of the 
aforementioned occurred, animals were euthanized with CO2 according to 
NIH guidelines. 
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Figure 1: Overview. Study outline consisted of a 4 hour baseline period followed by a 2 hour 
clamp period. Protocol could be adjusted as needed. © C. Buettner 
 
Rats were required to recover to within 10% of the pre-surgical body weight 
(BW) in order to become subject of the experiment. The rat was placed in a 
new cage with bedding and allowed ~15 minutes to habituate. 
 
1. Catheter Syringe Preparation 
a. For the arterial catheter: Attach a luer stub, made by blunting a 
23 gauge needle, to one end of 75 cm of PE 50 tubing. To the 
other end, attach a catheter coupler made from a doubly blunted 
23 gauge needle. 
b. For the venous catheter: Attach a luer stub, made by blunting a 
20 gauge needle, to one end of 75cm of PE 90 tubing. To the 
other end, attach a catheter coupler made by blunting a 20 
gauge needle and pulling it out of the plastic luer piece. 
 
2. Flush both pieces of tubing through with heparinized saline (40 U/ml) 
from 10ml syringes. 
 
3. To prevent rats from biting tubing, thread arterial and venous tubing 
through a plastic guard created by cutting the tip of a 1ml syringe 
cylinder. 
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4. Preparation of stereotaxic infusion 
a. Fill a Hamilton glass syringe with d-H2O, avoiding any bubbles 
in the syringe. 
b. Prepare a piece of PE50 tubing long enough to reach from the 
pump to the rat by attaching an infusion cannula to one end, and 
a 23 gauge luer stub (described in 1a) to the other. Flush the 
tubing through with water and insert the Hamilton syringe into 
the needle, there must not be any air in the infusion system at 
this point. Flush out any remaining water from the system. 
c. Aspirate 1 µL of air into the tubing to separate the d-H2O from 
the treatment, and then aspirate the desired treatment. 
d. Secure syringe to pump and prime the infusion system. 
 
5. Connecting Catheters 
a. Carefully, expose catheters without irritating the rat. 
b. Clamp tubing, remove venous catheter plug and insert catheter 
coupler attached to syringe (described above in 1). Draw back 
blood until it reaches the syringe, and flush so that the tubing is 
filled with heparinized saline and no blood. 
c. Repeat with arterial catheter. Once flushed, clamp arterial 
catheter syringe tubing with a hemostat. 
d. Remove dummy cannula and insert the primed infusion cannula 
to the stereotactically implanted guide cannula. Secure the 
infusion cannula to the guide with glue. Generally, the rats do 
not have to be restrained during these procedures. 
 
6. Blood Sampling 
a. Hold all syringes upright to avoid air bubble injection. 
b. Draw back blood from the arterial catheter until it reaches the tip 
of the catheter syringe. Clamp the line with hemostat, remove 
the syringe, and replace it with a 1ml syringe (“Dead Volume” 
syringe). 
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c. Draw back 0.5ml of blood (the dead volume), then insert a new  
syringe (the “Sample” syringe) and take a sample. 
d. Immediately re-inject dead volume, flush catheter and clamp 
with hemostat. 
e. Collect blood into an EDTA coated tube. Measure glucose 
(Analox GM9D, London, United Kingdom) and centrifuge for 2 
min. to collect plasma, saving 150µl for use in the insulin 
preparation described below (Step 8). 
f. Resuspend remaining blood cells in saline and reinject after 
each sample to minimize overall blood loss. 
 
7. Start brain infusion and timer (t = -120 min). Protocol outline depicted 
in figure 2. 
 
8. Solution preparations 
a. Insulin Solution, based on an infusion rate of 25 µL/min: prepare 
5ml of insulin mixture in a 10 ml syringe with a 23 Gauge luer 
stub consisting of: 
i. 150 µL plasma (5% plasma solution, to prevent insulin from 
sticking to PE tubing),  
ii. Insulin Dose, calculated as follows: BW (kg) * insulin dose 
(mU/kg/min) * 200 (conversion factor)  = µL of insulin from a 1 
mU/ml insulin stock, 
iii. 3 µg/kg/min, calculated as follows: BW (kg) * 1200 (conversion 
factor) = µl of a 0.5 µg/µl somatostatin stock, 
iv. Add saline to reach a total volume of 5ml. 
b. Glucose: Prepare about 3 ml of 25% glucose in a 10 ml syringe 
with a 23 Gauge luer stub. 
c. Tracer. 
 
9. Prepare the Infusion Tubing outlined in Figure 2. Prime glucose, 
insulin, and tracer lines and clamp each with hemostat.  
a. Prepare catheter coupler (as in 1b) to connect PE50 tubing to 
PE90 venous tubing and insert to Infusion Tubing. 
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b. Draw back blood into the venous catheter to visualize 















glucose syringe pump  
Figure 2:  Schematic outline for tubing preparation. © C. Buettner 
 
10. Collect a pre-clamp blood sample (t=120 min). Begin infusions by 
starting pumps and unclamping each line.  
a. Insulin infusion begins at a rate of 44 µL/min for 1 minute, 
followed by 25 µL/min until the end of the clamp. 
b. Set Glucose Pump rate according to insulin dose. For example, 
a 1mU clamp starts at 3 µL/min. 
c. Tracer infusion is initiated at t=0 min. 
 
11. Monitor blood glucose every 10-15 min and adjust Glucose Pump rate 
accordingly. Glucose infusion rate (GIR) is calculated based on BW 










Infused Glucose (g/L)×  Pump rate (µL/min)
BW (kg)×1000
 
12. Terminate clamp by injecting rat with ketamine slowly IV. 
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Figure 3: Clamp setup. Here we depict the setup utilizing an optional 2-channel swivel.    
                © C. Buettner 
Table 1: Specific reagents and equipment. 





Luer Stub 20 G 
 
BD BD305175 made from Precision 
Guide 20 G needle 
Luer Stub 23 G 
 
BD BD305193 made from Precision 
Guide 23 G needle 
Luer Stub 23 G for head infusion Instech LS23  
Catheter Couplers 20 G BD BD305175 made from Precision 
Guide 20 G needle 
Catheter Couplers 23 G 
 
BD BD305193 made from Precision 
Guide 23 G needle 












Flexible Silicone Tubing Instech BSIL-T015 0.015"ID x 0.078"OD 
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1 mL Syringe w/ Luer-Lok BD Syringe BD309602  
10 mL Syringe w/ Luer-Lok BD Syringe BD309604  
20 mL Syringe w/ Luer-Lok BD Syringe BD309661  
1700 Series Gastight 50µL 
Syringe 
Hamilton Co 60376-048  
Infusion Cannula System Plastics One 
Inc. 
 Consisting of guide 
cannula, dummy 
cannula and infusion 
cannula 
Swivel- 2 Channel Plastics One 
Inc 
  
Bulldog Serrefine Clamp, Curved Fine Science 
Tools Inc. 
18051-50  






Brain Infusion Pump Chemyx, Inc Fusion 400  















As mentioned previously, tissues were clamp frozen in liquid nitrogen and 
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2.2 Analytical methods 
 
2.2.1 Liquid scintillation counting 
In order to evaluate glucose uptake as well as endogenous glucose 
production (eGP), we used a continuous [3-3H]-glucose infusion as previously 
described. Blood samples for scintillation counting were drawn at appropriate 
time points for each experiment. The resulting plasma samples as well as 
tracer (diluted 1:10 with saline) were transferred to a fume hood to comply 
with radiation safety. Measurement of diluted total tracer activity was crucial 
as it accounted for auto-radiolysis occurring in radioactive chemical 
compounds.  
To each eppendorf tube, containing either 25 µL of diluted tracer or blood 
plasma, 50 µL of 0.3N Zinc Sulfate and 50 µL 0.3N Barium Hydroxide solution 
(both Sigma-Aldrich, St. Louis, MO) were added using a repeater pipette 
(Eppendorf, Hamburg, Germany) to deproteinate the samples. After briefly 
flicking the tubes, samples were centrifuged (Eppendorf, Hamburg, Germany) 
at 13,000 rpm for 5 min. 35µL  of the supernatant was then pipetted into a 96 
well plate for scintillation counting. To eliminate tritiated water the supernatant 
was dried overnight and reconstituted with water the morning after. Before 
counting 200 µL of Ultima Gold was added to each well, which were then 
covered with adhesive plate sealer and aluminum foil and placed on a rotating 
shaker for several hours (3-30 hours). For liquid scintillation counting the 
MicroBeta TriLux including proprietary software were used to assess counts 
per minute (cpm) per well. Specific activity of plasma glucose (cpm per mg 
blood plasma glucose) was then calculated and used to determine the 
glucose turnover rate from using its ratio to the [3-3H]-glucose tracer infusion 
rate.  
During the pre-clamp steady state conditions, eGP equals the glucose 
turnover rate. While eGP has to be calculated by subtracting the GIR from the 
glucose turnover rate during the pancreatic clamp period, the glucose 
turnover rate equals the rate of glucose disposal under steady state 
conditions.  
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60 104 0.00 992 37923 9.0 9.0
80 104 0.00 1079 41269 8.3 8.3
90 104 0.00 1023 39115 8.8 8.8
100 99 0.00 1026 41212 8.3 8.3
110 101 0.00 1043 41069 8.3 8.3
120 95 0.00 1176 49263 6.9 6.9
150 85.5 13 11.44 879 40842 8.4 -3.1
180 112.5 13.5 11.88 947 33458 10.2 -1.7
190 118 13 11.44 1004 33831 10.1 -1.3
200 117 13 11.44 945 32103 10.7 -0.8
210 122 13 11.44 894 29115 11.8 0.3
220 121 12.5 11.00 906 29752 11.5 0.5
230 121 12.5 11.00 935 30711 11.1 0.1
240 120 12.5 11.00 728 24067 14.2 3.2
0.00 0
GIR 11.33
Total Tracer (cpm) Rd 11.5
65790 Average GP Basal 8.5
55750 60770 GP Clamp 0.3
% Supp. 96.2%




Figure 4: Examplary spreadsheet of scintillation counting calculations in Microsoft    Excel. 
(GU= glucose uptake or Rate of disappearance (Rd), GP= glucose production) 
 
If not stated otherwise, all supplies for the liquid scintillation counts were 
purchased from Perkinelmer, Waltham, MA.  
 
2.2.2 Stable-isotope tracer 
The plasma rate of appearance (Ra) for glycerol and leucine was measured 
using plasma samples from 120 (basal), 180 and 240 (clamp) time points. 
While the Ra for glycerol reflects systemic lipolysis, the Ra of leucine serves 
as an index for endogenous whole body proteolysis (Heiling et al. 1993, 
Scherer et al. 2011). 
By using the following equation we were able to calculate the Ra based on 
the infusion rate (R in µmol/kg/min) and fractional isotopic enrichment of the 
infusion and plasma sample (ENRinf and ENRpl).  
Isotope enrichment was determined by GC/MS 
(realized by Michelle Puchowicz, Case Western Reserve University, OH). 
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2.2.3 Tissue preparation 
In general, tissue preparation and handling were conducted at cryogenic 
temperatures using liquid nitrogen and dry ice to prevent thawing and 
degradation of the tissue until protease inhibitors and appropriate buffers are 
added.  
For tissue homogenization in preparation for analysis of amino acids, 
acylcarnitines, organic acids, and acyl coenzyme, liver samples were 
pulverized using a liquid-nitrogen-chilled 3-pound sledge hammer by placing 
the samples in a pre-chilled pouch made out of extra heavy duty aluminum 
foil. Pulverized tissue was afterwards stored at -80°C until homogenization.  
Before homogenization the liver samples were weighed and placed on dry 
ice. For preparation of tissue samples for western blot analyses, lysis buffer 
was added to tissue samples according to table 2. 
 
Tissue Liver Hypothalamus Muscle Fat 
Weight 100mg Big Small  100mg 100mg (200mg 
obese animals) 
Tube 5ml 2ml  2ml 5ml 2ml 
Lysis 
buffer 
1ml 100µL 80µL 500µL 500µL 
Table 2:  Amount of lysis buffer to be added per individual tissue 
 
High-performance liquid chromatography (HPLC) grade water (450µL)  per 
50mg tissue or 1900µL per 100mg tissue and an equal mixture of isopropanol 
and 0.1 M KH2PO4 (all Sigma-Aldrich, St. Louis, MO) were added to 
pulverized liver samples, later on subjected to mass spectrometry. 
Irrespective of the assay, samples were homogenized (Tissue Tearor, 
BioSpec Products, Inc., Bartlesville, OK) for 20 seconds. In between two 
samples, the homogenizer was washed with ethanol and rinsed twice with 
deionized water (dH2O). 
Mass spectrometry samples were refrozen and send out to our collaborator  
for analyses (Metabolomics Laboratory, Sarah W. Stedman Nutrition & 
Metabolism Center, Duke University Medical Center, Raleigh, NC). 
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Samples for western blotting analyses were sonicated (Sonifier 250, Branson 
Ultrasonics Corporation, Danbury, CT) at the lowest setting for additional 15 
seconds, cleaning the sonicator in between samples with ethanol once and 
twice with dH2O. The tubes were then transferred to a cooled centrifuge 
(Eppendorf, Hamburg, Germany) at 4°C (Fat: 0°C) and spun down for 20 min 
at 13,000g. The resulting supernatant was afterwards transferred to 1.5 ml 
eppendorf microtubes and stored on ice. 
 
Lysis buffer was prepared using 40mM beta glycerophosphate, 2mM sodium 
orthovanadate, 20mM 3-(N-morpholino)propanesulfonic acid (MOPS), 30mM 
sodiumflouride, 10mM sodium pyrophosphate, 2mM ethylene glycol 
tetraacetic acid (EGTA), 5mM Ethylenediaminetetraacetic acid (EDTA) and 
1Lof deionized water as solvent (all purchased from Sigma-Aldrich, St. Louis, 
MO). One tablet of light sensitive protease inhibitor (Roche, Nutley, NJ) was 
added to 50ml of buffer in an aluminum wrapped tube before use. 
 
2.2.4 Protein assay 
The protein assay served as a crucial tool for adjustment of different total 
protein concentrations and allowed us to evaluate specific enzyme levels and 
their activity, respectively. We used the Pierce bicinchoninic acid (BCA) 
Protein Assay Kit (Thermo Scientific, Waltham, MA) to determine the total 
protein concentration. After successful tissue preparation, the aforementioned 
supernatant of each sample was pipetted to a 96 well plate as shown in table 
2 and diluted with water according to its tissue of origin (shown in table 4). 
Bovine serum albumin (BSA, Sigma-Aldrich, St. Louis, MO) was used as 
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 1 2 3 4 5 6-12 
A BSA A BSA A Sample 1 Sample 1 Water  
B BSA B BSA B Sample 2 Sample 2 Water  
C BSA C BSA C Sample 3 Sample 3 Buffer  
D BSA D BSA D Sample 4 Sample 4 Buffer  
E BSA E BSA E Sample 5 Sample 5   
F BSA F BSA F Sample 6 Sample 6   
G BSA G BSA G Sample 7 Sample 7   
H BSA H BSA H Sample 8 Sample 8   
Table 3: Sample plate layout for a protein assay for 8 samples. 
 
 
 Liver Hypothalamus Muscle Fat 
dH2O 19µl 18µl 18µl 18µl 
Sample 1µl 2µl 2µl 2µl 
BSA 20µl 20µl 20µl 20µl 
Table 4:  Sample volumes for different tissue (adjustment if total protein concentrations 
are not in between BSA standard concentrations). 
 
The BCA protein assay reagent formed by mixing reagent A and B at a ratio 
of 50:1 and 200 µL was added to each sample containing well. The plate was 
sealed and and incubated at 37°C. After 30 mins the plate was put on ice for 
1 min and inserted in our spectrophotometer (Multiskan® Spectrum, Thermo 
Scientific, Waltham, MA), measuring absorbance at a wavelength of 620nm. 
 
Average standard BSA levels were measured and a linear trendline was 
plotted, which allowed us to determine the total protein concentration of our 
samples.  The coefficient of determination R2 was determined using Microsoft 
Excel built- in -function and accepted if R2 was 0.99 or above (Example 
shown in figure 5). 




After determination of the concentration, samples were diluted with lysis 
buffer to a final concetration of 3-4 µg/µL total protein for western blot 
analysis. 
2.2.5 Western blotting  
Western blotting allowed us to measure key enzymes in treated animals and 
compare their relative quantity to that in control groups, reflecting the in vivo 
up- or down-regulation of those proteins and/or their phosphorylation and 
therefore activated or inactivated state during the experiment.  
It consists out of several steps starting with gel electrophoresis (running the 
gel), transfer of proteins to a membrane (the actual blot or transfer), 
application of specific primary antibodies (ABs) to desired proteins (primary 
antibodies) and probing the membrane with secondary ABs against primary 
ABs for visualization. Dependent on the amount of light emitted after 
excitation the relative quantity could be calculated, since it is directly 
proportional to the emitted light of a specific wavelength (direct fluorescence 
measurement at 680 and 800nm).  
 
Gel electrophoresis 
Our usual electrophoresis setup consisted out of precast 4-12% NuPage® 
gels, XCell SureLock® electrophoresis chambers, NuPage® MOPS sodium 
dodecyl sulfate (SDS) Running Buffer, NuPage® Antioxidant and a ZOOM® 
Dual Power Supply (all Invitrogen, Carlsbad, CA). 
 
Diluted samples were mixed with loading buffer (93.3µL buffer per 200µL 
sample) to denature and reduce the proteins. Samples were then heated 
Figure 5: Sample protein standard curve. 
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(Accublock, Labnet International, Woodbridge, NJ) to 85°C for 5 minutes and 
put on ice. Each well of the gel was then flushed and filled with the prepared 
sample ideally yielding a total protein load of 20 µg. A protein marker 
(Odyssey Protein Molecular Weight Marker 10-250 kDA, LI-COR, Lincoln, 
NE) was added to later on identify proteins based on their molecular weight. 
The marker as well as the dyed bands of each sample helped us to determine 
an even separation between samples, as ideally all samples built a horizontal 
line at the bottom of the gel after an electrophoresis. It usually took 2 hours at 
110 volts to successfully run each electrophoresis experiment. 
 
Transfer 
To transfer the proteins, blot membranes (Immobilon FL PVDF, Millipore, 
Billerica, MA) were cut, labeled, rinsed with methanol and stored in transfer 
buffer 10 to 20 min before end of the gel electrophoresis. Then gels and 
membrane were carefully placed in between filter paper and soaked in 
transfer buffer. Transfer buffer soaked sponges were put around the gel-
membrane sandwich and put into a transfer chamber (XCell II Blot Module, 
Invitrogen). After filling the chamber with transfer buffer, the front and rear 
parts of the tank were filled with ice to cool the chamber during the transfer. 
The transfer itself usually took another 2 hours at 200mA followed by blocking 
the membranes at room temperature for 1 hour using Odyssey LI-COR 
Blocking Buffer (LI-COR, Lincoln, NE) 1:1 diluted in TBS.  
Membranes were then put into tubes containing the desired primary ABs and 
incubated at 4°C overnight. 
 
Scanning and analysis 
The morning after, each membrane was washed three times for 5 minutes 
with TBS-T (0.1%) on a rocking shaker. Following the third wash, blots were 
incubated for 1 hr at room temperature in 15 ml blocking buffer containing 
0.1% TBS-T and 0.1% SDS, Dylight 680-conjugated goat anti-rabbit IgG and 
Dylight 800-conjugated goat anti-mouse IgG (both Thermo Scientific, 
Waltham, MA). Since the secondary antibodies are light sensitive, the 
washing boxes were covered with aluminum foil during the incubation. 
Following three washes with TBS-T and final wash with TBS, blots were 
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analyzed for fluorescence. For direct fluorescence measurement and 
quantification we used the LI-COR Odyssey scanner (LI-COR, Lincoln, NE) 
and Odyssey 3.0 software. Protein identification was based on molecular 
weight, antibodies used and color (red or green), as non-specific bands 
appeared in some used antibodies. After quantification we normalized each 
sample to corresponding housekeeping (GAPDH, α–tubulin or β–actin) that 
was not altered by treatment to adjust for possible unequal loading volumes 




All reagents were purchased from Sigma-Aldrich if not mentioned otherwise. 
Loading buffer: 5ml NuPage® LDS sample buffer 4x + 2ml 
NuPage® sample reducing agent 10x (stored at 
4°C, both Invitrogen, Carlsbad, CA) 
TBS-T:    1l of 20x TBS + 19l of dH2O + 20ml of Tween®. 
TBS:     500ml of 20x TBS + 9.5l of dH2O 
Transfer buffer:  1l 10x Transfer Buffer + 7l of dH20 + 2l methanol. 
Blocking buffer:  25ml blocking buffer (LI-COR, Lincoln, NE) + 25ml 
of 1x TBS (1:1) 
Primary antibody:  Blocking buffer and 1x TBS/T at 1:1 ratio. Add 
antibody to get recommended dilution.  
Example:  Cell Signaling AB: 2.5ml blocking 
buffer + 2.5 TBS/T + 5μl AB.  
(1:1000) 
Secondary antibody:  50ml TBS/T + 50μl SDS 10% + 8.3μl anti-rabbit 
(1:6000)+ 6.3ul anti-mouse (1:8000, both Thermo 
Scientific, Waltham, MA) 
20x TBS: 484g tris base + 1600g NaCl + 10l dH2O + HCl to 
pH of 7.6 
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Primary antibodies 
Antibodies against the following proteins mentioned in this thesis are:  
Acetyl-CoA carboxylase (ACC), α subunit of AMP-activated protein kinase 
(AMPKα), Ampkα Thr 172 phosphorylated (pAMPK, all Cell Signaling 
Technology, Beverly, MA), Fatty acid synthase (FAS, BD Bioscience, San 
Jose, CA), α–tubulin, β–actin and Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH, all Abcam, Cambridge, MA) 
 
2.2.6 Assays 
Free fatty acids (FFAs, NEFAs), triglycerides (TG) and free-glycerol were 
measured in plasma using a colorimetric enzyme linked assay by Wako 
Chemicals (Richmond, VA) and Sigma-Aldrich (St. Louis, MO).  
 
Free-glycerol and triglyceride assay 
The serum triglyceride determination kit allowed us to measure free-glycerol 
as well as total triglyceride concentration in one assay, which measured 
glycerol concentration through a chain of enzymatic reactions (figure 6, 
adapted from kit insert) resulting in a dye. The dye's absorbance is directly 
proportional to the plasma glycerol concentration, either deriving from free-
glycerol or triglycerides. As plasma triglycerides are bound to proteins, 
lipoprotein lipase (triglyceride reagent) was added in order to break down 
triglycerides into glycerol and fatty acids.  
The spectrophotometer 
was set to a wavelength 
of 540nm and calibrated 
to zero with water. Then 
a 96 well plate with 
blank, sample and 
standard wells each 
containing free glycerol 
reagent was prepared 
and water, sample or 
glycerol standard added accordingly. After incubating the plate for 5 minutes 
Lipoprotein Lipase
Triglycerides Glycerol + Fatty acids
GK
Glycerol + ATP G-1-P + ADP
GPO
G-1-P +   O2 DAP + H2O2
POD
H2O 2 + 4-AAP + ESPA Quinoneimine dye + H2O
Figure 6:  Triglyceride assay schematics 
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at 37°C we read out our initial measurement of absorbance (IA), added 
triglyceride reagent and incubated the plate for another 5 minutes. Final 
absorbance (FA) was measured and concentrations were calculated by 
division of IAsample - IAblank and IAstandard - IAblank multiplied with the 
concentration of the standard for free-glycol concentration. For triglyceride 
concentration we repeated the calculation with FA instead of IA readings.  
 
Free fatty acid assay 
Similar to the previous assay, NEFA levels were determined by measuring the 
absorbance of a dye (figure 8, adapted from kit insert) directly proportional to 
NEFA levels. For 
calibration we used the 
NEFA standard from 
Wako Chemicals 
(Richmond, VA). The 
spectrophotometer was 
set to 550nm at 37°C. 
300µL of Color Reagent A 
Solution were added to 
7µL per sample and used 
as sample blank. Then 
150µL of Color Reagent B 
Solution were added and 
the sample absorbance 
was measured after 4.5 
mins. Concentrations were calculated in mmol using a standard curve for 
NEFA as described for the protein assay.  
 
Glutamate-dehydrogenase activity assay 
Glutamate-dehydrogenase catalyzes the reaction from glutamate to α -
ketoglutarate and vice versa. By artificially oversaturating glutamate in the 
samples, we were able to measure the enzymes activity through the elevation 
of Nicotinamide adenine dinucleotide (NADH), a coenzyme of the reaction, 
which was measured colorimetrically (λ=450nm). Contrary to the previous 
R-COOH + ATP + CoA 
  ACS





























Blue  purple  pigment
OH-  +  3H2O
Figure 7: NEFA assay schematics 
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assays, this activity assay measures the signal multiple times in short 
intervals so a kinetic curve could be plotted.  Where the activity was higher, 
the substrate was exhausted more quickly and only that part of the curve that 
resembled a linear function numerically was chosen for further analyses. The 
average activity and specific activity was then calculated based on the 
absorbance of NADH standard solutions included in the used kit (BioVision, 
Mountain View, CA). Due to the proprietary nature of the kit, a detailed 
description of its ingredients was not available upon request (link current as of 
April 26th 2013: http://www.biovision.com/glutamate-dehydrogenase-activity-
colorimetric-assay-kit-4019.html). 
 
2.2.7 Metabolomics analysis 
To detect various metabolites in liver and plasma samples provided by us, a 
stable-isotope dilution followed by either flow-injection tandem-mass 
spectrometry (MS-MS) for amino acids (AAs) and acylcarnitines (ACs), or gas 
chromatography-mass spectrometry (GC/MS) for organic acids (OAs) was 
used (Ferrara et al. 2008, Turer et al. 2009). Acyl-CoA metabolites were 
assessed by solid-phase extraction followed by flow-injection mass 
spectrometry (Monetti et al. 2007). Internal standards for AAs, ACs and OAs 
were labeled with heavy stable isotopes while acyl-CoA analysis was based 
on spiking with C17 coenzyme A. Metabolomics analysis was performed in 
the Sarah W. Stedman Nutrition & Metabolism Center under the direction of 
Christopher B. Newgard, PhD. 
 
Mass spectrometer 
A mass spectrometer (MS) consists of three essential components, the 
ionization source, the mass analyzer and the detector. The sample is first 
introduced into the ionization source where the molecules are ionized before 
being separated by electromagnetic fields and detected based on their mass 
(m) to charge (z) ratio (m/z) spectra. To ensure unhindered separation, 
analyses are usually conducted in a vacuum. Each molecule (ion) has a 
distinct m/z ratio by which it can be identified. Biological samples however, 
contain a plethora of different molecules, which makes it difficult to reliably 
identify each of them by MS alone, so the samples need to be separated 
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before introduction to the ionization source (gas chromatography, high 
pressure liquid chromatohraphy) or broken down further after a first reading 
(tandem-MS).  
 
Tandem mass spectrometer 
A tandem mass spectrometer usually has two analyzers that are separated by 
a collision cell into which an inert gas, such as xenon is admitted to collide 
with the sample ions and fragment them. The ions characteristic 
fragmentation pattern improves the reliability of identification. 
 
Gas chromatography 
As explained earlier, several methods for pre-separation are available. The 
method primarily used in our studies was gas-liquid chromatography. Its 
principle is based on an inert gas carrying the vaporized sample, called 
mobile phase and a layer of liquid inside a tube called stationary phase. As 
the gaseous mixture flows through the tube (column), the mobile phase 
interacts with the stationary phases in the column, which leads to the elution 
of each component at a different time called retention time. By analyzing each 
components specific elution and retention time, a first qualitative detection of 
most molecules can be made before entering the mass spectrometer. 
 
Solid-phase extraction 
Analog to gas chromatography, solid-phase extraction consist of a mobile and 
a stationary phase with the difference that the mobile phase is liquid while the 
stationary phase is solid. After passage of the mobile phase through a 
cartridge containing the stationary phase, either the solid or liquid extract is 
kept, dependent on which extract contains the desired components. 
 
Flow-injection 
Flow-injection is an automated method to increase precision of the otherwise 
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Stable-isotope dilution 
For highly reliable quantification of metabolites, a stable-isotope dilution 
method was used. Stable-isotope standards are added to the analyte and 
equilibrated before being subjected to MS-MS or GC/MS, thereby allowing 
quantitative analyses.  
 While doing experiments for mass spectrometry we did not use radioactive 
tracer, as radioactive isotopes could potentially lead to contamination of the 
MS. We decided to repeat experiments with radioactive tracer at a later time 
point, to increase group size (n=4 per group for non-radioactive samples) and 










3.1 Basic data 
Differences in bodyweight, age or glucose levels could heavily affect 
metabolism or the reaction to a stimulus, such as central leptin or insulin. 
Therefore animals were matched based on these parameters and plasma 
glucose levels were balanced as accurately as possible. A pancreatic clamp 
serves as the experimental gold-standard for evaluation of peripheral insulin 
sensitivity/resistance. It allows the investigator to simulate defined insulin and 
glucose levels, while measuring glucose uptake and production via tracer 
dilution techniques, 
without interference 
from the endocrine 
part of the pancreas, 
which is disabled by 
continuous infusion of 
somtatostatin. 
As depicted in table 
5, in each experiment 
two or three different 
groups were 
examined, and consisted of one control group (MBH aCSF) and one or two 
treatment groups. All rats were 10-12 weeks old at the time of the clamp and 
weighed around 300g. Although the MBH aCSF and MBH ins groups seem 
lighter than the MBH lep group in the stable tracer experiment, no significant 
differences could be found. 
During the course of the clamp, glucose levels were monitored and adjusted 
to euglycemic levels, as necessary.  
Elevated GIR could be a first sign of suppressed endogenous or hepatic 
glucose production and is shown in the following figures as average over the 
entire clamp period as well as average per measured time point. Interestingly 
the GIR of the stable tracer group are higher compared to the radioactive 
Stable isotope tracer MBH aCSF MBH ins MBH lep
Group size 3-4 4 4
Age (weeks) 10.8 ± 0.3 10.5 ± 0.1 10.9 ± 0
Bodyweight (g) 274 ± 5 274 ± 7 307 ± 20
Plasma glucose (mg/dl) 128 ± 8 122 ± 3 126 ± 4
Radioactive tracer MBH aCSF MBH lep
Group size 7 4-5
Age (weeks) 11.3 ± 0.1 11.6 ± 0.2
Bodyweight (g) 326 ± 11 311 ± 7
Plasma glucose (mg/dl) 130 ± 4 120 ± 7
Table 5: Bodyweight, average plasma glucose, age and 




tracer group receiving the same treatments (figure 8 C, F). This observation 











Figure 8 A-F:  Plasma glucose levels in mg/dl and glucose infusion rate in mg/kg/min are 
shown as mean ± standard error of the mean (SEM). Experiments conducted with radioactive 
tracer are labeled with a radioactivity sign in the upper right corner (* P < 0.05; ** P < 0.01, 
student’s two-tailed unpaired t-Test) 
 
As shown in figure 8 E and F, GIR of the leptin treated animals is markedly 
increased compared to the control group. Nonetheless the same effect was 
not seen in the group receiving stable tracer (figure 8 B and C).  
3.2 Tracer calculations 
3.2.1 Radioactive tracer 
Hepatic glucose production in the MBH leptin group remained similar to the 
control group in the basal period while its suppression was markedly 
increased during the clamp period (figure 9 A;B). Rate of glucose disposal 
however was unaffected in both groups (figure 9 C). 
 
–120 min 0 120 240
clamp period
[2H–5]–Glycerol (1 !mol*min-1*kg-1)








Figure 9 A-D: Hepatic glucose production (hGP), suppression of hGP, rate of 
glucose disposal (Rd) and scheme for the MBH leptin treated group 
receiving radioactive tracer instead of stable- isotope tracer. 
Results shown in mean ± SEM (* P < 0.05, student’s two-tailed 




3.2.2 Stable-isotope tracer 
Analysis of plasma samples containing stable-isotope tracer (figure 10 A,B), 
showed significant decrease in Ra glycerol, indicating suppressed lipolysis, as 
previously described (Scherer et al. 2011). Although Ra leucine was lower in 
the insulin treated group it failed to reach statistical significance during the 


















Figure 10 A,B: Ra glycerol and Ra leucine in µmol/kg/min and mg/kg/min respectively. 




3.3 Triglyceride, free glycerol and NEFA plasma levels 
 
To properly assess energy metabolism, we determined plasma triglyceride, 
free glycerol and NEFA levels before start of the experiment (-120) as well as 
during the basal (120) and clamp (240) periods. As depicted in figure 12 
neither the groups receiving stable-isotope (figure 11 A-C) nor the groups 
receiving radioactive tracer (figure 11 D-F) showed any significant change 






Figure 11 A-F: Plasma triglyceride, free glycerol and NEFA levels in either µg/ml or 
mmol), n=4 for non-radioactive, n=5 for radioactive MBH leptin, n=7 
for radioactive MBH aCSF. Results shown in mean ± SEM (* P < 





Metabolomic analyses of both liver and/or plasma samples enabled 
determination of the amount of acyl-CoA and acylcarnitine per sample. 
Results have been segregated into short chain(chain length between C2-C6), 
medium chain(C7-C12), and long chain (C13-C22) groups to point out the 
most important ones separately.  
 
3.4.1 Plasma sample analysis 
We analyzed plasma samples from the start (t = -120 min) and the end (t = 
240 min) of the experiment to separate changes in metabolites that are clamp 
related from changes caused by our administered treatment. The samples 
taken at time point t = -120 min were examined for significant differences 




The ratio from samples taken at t = 240 min and t = -120 min was calculated 
and shown in figure 12. A value lower than 1 reflects a decrease over the 
course of the experiment, while a value above reflects an increase. As 
depicted in figure 12 A alanine as well as histidine increased in all groups, 
while the increase in valine, leucine/isoleucine, phenylalanine and ornithine 
seen in the control group could not be shown in treatment groups.  
 
Acylcarnitines 
Medium chain acylcarnitines decreased in the control group as shown in 
figure 12 B, while short and long chain acylcarnitines remained unaffected. 
Significance was tested between control and treatment group from total 





3.4.2 Liver sample analysis 
Metabolites from liver samples were analyzed using their concentration 
normalized to the control groups’ metabolite concentration (µM metabolite per 
µg/ml total protein concentration). Alanine levels were markedly increased in 
the MBH leptin group, while glycine, methionine, histidine, tyrosine levels 
were moderately increased in MBH insulin treated animals. Phenylalanine, 
glutamine + glutamate levels were slightly elevated and asparagine + 
aspartate levels in the MBH leptin group showed a 50% decline in comparison 
to control animals (figure 13 A:B). Organic acid levels developed the biggest 
fold change in treated animals with up to 5-fold change in pyruvate and 3-fold 
in lactate levels. Fumarate levels were significantly higher in the MBH leptin 
group as well (figure 13 C). Although long chain acylcarnitine levels were up 
to 50% decreased, they failed to reach statistical significance. Short chain 
Acyl-CoA levels on the other hand expressed a significant increase in both 
treatment groups. The metabolically most significant CoA complexes 
including Coenzyme A itself are depicted in Figure 13 F. Acetyl-CoA and 
CoA-SH concentrations are elevated in both MBH insulin and leptin groups, 
as malonyl-CoA and succinyl-CoA are in the MBH leptin group. 
Figure 12 A,B: Plasma amino acids and 
acylcarnitine level ratio. 
Results shown in mean 
± SEM (* P < 0.05, 
student’s two-tailed 
unpaired t-Test), n=3 for 
MBH aCSF, n=4 for 






Figure 13 A-F: Liver amino acids, 
acylcarnitine and acyl-CoA 
level ratio. Results shown 
in mean ± SEM (* P < 
0.05, ** P < 0.01 student’s 
two-tailed unpaired t-Test), 
n=3 for MBH aCSF, n=4 






3.5 Western Blots 
 
Quantification by western blot produced inconsistent data as phosphorylated 
AMPKα and AMPKα increased 
significantly in some groups 
receiving stable-isotope tracer, 
while the same increase could 
not be shown in a repeated 
experiment using radioactive 
tracer (figure 14 B;C). Figure 14 
A shows an exemplary image of 
AMPKα and β–actin quantified 
in figure 15 B. The analyzed 
proteins were selected based 
on their importance in fatty acid metabolism (Abu-Elheiga et al. 2001, 

















Figure 14 A-D: A: Western blot of AMPKα (green) and β-actin (red) indicated by white 
arrows, B;C: Normalized ratio of proteins analyzed by western blot. D: 
Normalized ratio of liver acylcarnitines. Results shown in mean ± SEM (* P < 
0.05, student’s two-tailed unpaired t-Test, L2 stands for the same AB 




3.6 Glutamate dehydrogenase activity 
 
We assessed the activity of GLDH which catalyzes the reaction of glutamate 
to α-ketoglutarate and vice versa, and both substrates showed an increase in 
their liver levels (figure 13 B;C). Interestingly, there was an increase of at 
least 50% increased activity in the MBH insulin group compared to control, 








Figure 15: Specific activity of glutamate-dehydrogenase in 
mU/mg protein. Results shown in mean ± SEM 






4.1 MBH leptin and insulin ameliorate insulin resistance, 
suppress long chain fatty acid oxidation in the liver and lead to a 
decrease in circulating BCAAs 
Central leptin and insulin suppress long chain fatty acid β -oxidation in 
the liver and promote switch from lipid to carbohydrate and amino acid 
utilization. 
Despite central insulin and leptin’s opposing role in regulating metabolism in 
adipose tissue (Buettner et al. 2008, Scherer et al. 2011), their role in 
regulating hepatic metabolism, seems to act synergistically as supported by 
our results, showing a decrease in long chain acylcarnitines as well as 
anaplerosis of tricarboxylic acid (TCA) cycle intermediates in both treatment 
groups.  An increase was found in both treatment groups in pyruvate, lactate 
and alanine that are crucial for gluconeogenesis. This accumulation of 
metabolites implies either a suppression of gluconeogenesis, increased 
glycolysis, increased hepatic uptake of those intermediates or suppression of 
substrates entering the TCA cycle. The concentration of these intermediates 
may reflect increased flux through the TCA cycle. Consistent with decreased 
substrate flux into the TCA cycle, we did not see an increase in liver citrate 
levels, but surprisingly most measured TCA cycle metabolites were either 
significantly elevated or showed a clear trend in both insulin and leptin treated 
animals compared to the vehicle group (figure 13 C;F), which argues against 
decreased flux into the TCA cycle (Koves et al. 2008), as decreased influx 
would result in decreased metabolite levels, while increase in metabolites 
could either be caused by impaired cataplerotic reactions or overall increase 
of flux. 
Anaplerotic reactions lead to an increase of TCA cycle intermediates and 
usually are in balance with cataplerotic reactions, such as fatty acid synthesis 
and gluconeogenesis (Owen et al. 2002), that lead to a decrease in TCA 
cycle intermediates. Decreased gluconeogenesis or fatty acid synthesis could 
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therefore account for the observed anaplerosis. The elevated Acetyl-CoA 
levels are in line with the overall increase of glycolysis metabolites, but could 
also be a consequence of suppressed fatty acid synthesis.  
Cataplerotic reactions include disposal of TCA cycle intermediates to avoid 
accumulation (Owen et al. 2002). Such reactions are catalyzed by 
phosphoenolpyruvate carboxykinase (PEPCK), glutamate dehydrogenase 
(GLDH) or aspartate aminotransferase. We therefore analyzed GLDH activity 
and found a significant increase in insulin treated animals, supporting an 
increase in TCA cycle flux. 
 
Whereas aforementioned intermediates (mainly glucose intermediates) 
homogeneously increased, intermediates specific for fatty acid metabolism 
differed dependent on their length and the analyzed tissue. 
Short chain Acyl CoAs in liver tissue increased significantly in both treatment 
groups by at least 50%. Medium Chain Acyl CoAs seemed to increase and 
long chain Acyl CoAs even decreased, but the results were not statistically 
significant as shown in figure 13 E.  
Since Acyl CoAs occur in the cytosolic as well as in the mitochondrial fraction 
of the cell, it is impossible to say in which compartment the increased or 
decreased intermediates appear without isolation of individual sub-
compartments such as mitochondria or the cytosol. Carnitine Acyltransferases 
accelerate the reaction that is necessary for Acyl-CoAs to pass the 
mitochondrial membrane, by binding the acyl rest to carnitine in exchange for 
CoA (Ramsay et al. 2001). Therefore acylcarnitine levels can be used to 
estimate fatty acid flux through these membranes and lipid load of 
mitochondria before β -oxidation and oxidative phosphorylation (Koves et al. 
2008). Short chain Acyl carnitine levels in liver tissue were slightly elevated, 
while medium chain Acyl carnitine levels were not altered. Long chain 
acylcarnitines in turn were markedly decreased (figure 13 D), which could be 
due to suppression of a rate-limiting enzyme in fatty acid β-oxidation, carnitine 
palmitoyltransferase 1 (CPT-1) (Doh et al. 2005). Malonyl-CoA inhibits CPT-1 
activity and its level was significantly increased in leptin treated animals, 
supporting our theory from the observed decrease of long chain acylcarnitine 
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levels, that MBH leptin and insulin suppress oxidative phosphorylation of long 
chain fatty acids in the liver. 
Even chain acylcarnitines with a chain length equal to or larger than six 
carbon atoms derive from fatty acids, while most shorter chain length 
acylcarnitines and acyl-CoAs like C3 and C5 species derive from amino acid 
catabolism (Bhuiyan et al. 1988). Systemic administration of leptin or insulin in 
mice deficient of endogenous insulin was previously reported to normalize 
hepatic metabolite levels and might further improve DM management if given 
in combination (Wang et al. 2010). More specifically hepatic acylcarnitine and 
amino acid levels were lowered in treated animals compared to untreated 
diabetic rats. 
 
Metabolite levels in pathways processing substrates from all nutrient sources 
(lipids, carbohydrates, amino acids) increased in MBH insulin or leptin treated 
animals, while fatty acid derived acylcarnitines in turn are markedly 
suppressed. This observation can be explained through preference of 
carbohydrate or amino acid metabolites over fatty acid metabolites in nutrient 
fluxes. 
 
MBH insulin alters hepatic protein synthesis 
Interestingly MBH insulin significantly increased liver levels of many essential 
amino acids like Histidine or Methionine as well as branched-chain amino 
acids (BCAAs). 
Since most of the appearing amino acids are essential, this observation 
cannot be explained by increased production. One possibility would be 
increased proteolysis, while another one would be reduced aminoacid 
utilization through suppression of protein synthesis in the liver through MBH 
insulin. Since the animals were fasted before the start of the clamp, change in 
amino acid uptake from the gut is unlikely to account for this difference. While 
proteolysis usually appears in muscle tissue first (Cahill 2006, Goodman et al. 
1981), one would expect a rise in the aforementioned amino acids in plasma. 
In fact plasma metabolite analysis showed the opposite, as most of the amino 
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acids where decreased compared to control, explainable through increased 
utilization in peripheral tissues. 
Alanine however, which is important for the transport of glucose and amino 
acid metabolites from muscle tissue to the liver (Felig 1973) was 1.5-2 fold 
increased in blood plasma after the clamp in all groups. This increase could 
be due to enhanced protein turnover, decrease in oxidative phosphorylation, 
ureageneis or gluconeogenesis (Schutz 2011) proteolysis in muscle tissue is 
a likely cause (since the rats transition into an early fasting state). Ra of l-
leucine however did not increase, as one would expect when proteolysis 
occurs. 
Isovalerylcarnitines (C5) in liver tissue were significantly increased in MBH 
insulin treated animals, consistent with the observed increase in amino acids 
and supportive for enhanced amino acid catabolism rather than suppression 
in protein synthesis. Consistent with the idea of increased amino acid uptake 
in the liver is the increase of several metabolites involved in branched-chain 
amino acid catabolic pathways such as glutamate, alanine, aforementioned 
C5-acylcarnitine and acetyl-CoA.  
Overall protein synthesis in the liver might even be increased due to 
enhanced amino acid uptake from the bloodstream, which could explain the 
decreased amino acid levels we see in the plasma as well as the increased 
amino acid levels in liver tissue.  
It is possible that proteolysis in muscle tissue occurs while amino acid uptake 
in the liver increases, resulting in the observed minor change in the rate of 
appearance of l-leucine.  
As our observations in amino acid flux varied and reliable implications for 
protein regulation could not be made at this point, we subjected liver samples 
to proteomic analysis. The results of this analysis will be incorporated in a 
follow up study. 
MBH leptin and MBH insulin’s effect on fatty acid synthesis in liver 
tissue 
Prolonged high fat feeding, a model for common forms of obesity and insulin 
resistance in humans leads to hypertriglyceridemia, insulin resistance, 
hyperinsulinemia and hyperleptinemia, the latter a manifestation of a 
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compensatory response to both leptin and insulin resistance. Further, 
prolonged high fat feeding is known to lower fatty acid derived acylcarnitines 
in the liver (Koves et al. 2008), such as long and medium chain acylcarnitines, 
indicating decreased mitochondrial fatty acid β-oxidation, likely due to insulin 
resistance.  
Whether the decreased long chain acylcarnitines in our model are caused 
only by decreased β-oxidation or also increased fatty acid synthesis remained 
unclear, since Malonyl-CoA was elevated predicting CPT1b inhibition, but key 
enzymes explaining its increase, such as pACC, ACC were not altered in 
western blot analysis of liver tissue (figure 14 B;C). In fact the α-subunit of 
AMPK, which affects numerous downstream pathways including increased 
fatty acid oxidation (Hardie 2004, Orci et al. 2004, Shaw et al. 2004), even 
showed a significant increase in animals of both treatment groups. AMPK-α 
phosphorylated at Thr 172, indicating an activated state of AMPK (Hawley et 
al. 1996), was only increased in the MBH leptin group (figure 14 A). Malonyl-
CoA itself inhibits CPT-1 allosterically (Brady et al. 1993) giving further proof 
of suppressed β-oxidation. It serves as main substrate for fatty acid synthase, 
whose enzyme concentration was not altered by MBH insulin or MBH leptin in 
western blot analysis (figure 14 B;C). Due to the controversial results it was 
not possible to clearly assess if MBH leptin and insulin increase fatty acid 
synthesis.  
 
MBH leptin suppresses hepatic glucose production  
When we repeated the MBH leptin experiments previously conducted with 
stable-isotope tracer we were able to see a significant suppression of hepatic 
glucose production (figure 9 B)  
As MBH leptin did not suppress hGP in the basal period, in fact even showed 
a non-significant increase, it only assisted insulin in hGP suppression during 
the clamp period. This observation is consistent with previous studies (Pocai 
et al. 2005b), implicating that central leptin is able to restore hepatic insulin 
sensitivity in rats receiving a high-fat diet. Pocai et al showed 
intracerebroventricular (ICV) leptin to increase gluconeogenesis, through 
upregulation of PEPCK and glucose 6-phosphatase (G6Pase), while 
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decreasing glycogenolysis, resulting in no change in net hGP. In overfed rats 
on the other hand ICV leptin lead to a decrease of both PEPCK and G6Pase, 
without change of gluconeogenesis, resulting in suppression of overall hGP. 
By infusion into the MBH our study was able to further localize a region in the 
brain that seemed to enable leptin to decrease hGP in rats receiving regular 
chow. Comparison with earlier studies would therefore suggest that MBH 
leptin suppresses glycogenolysis. In fact suppression of glycogenolysis by 
ICV leptin is part of an MSH independent neuronal pathway, while 
gluconeogenesis is believed to be regulated through MSH dependent 
pathways (Gutierrez-Juarez et al. 2004). It is likely that our model of MBH 
leptin selectively regulates hGP and hepatic metabolism through MSH 
independent pathways. 
MBH leptin did not affect insulin sensitivity in other peripheral tissues, as Rd 
of glucose was not affected by systemic insulin, which in part is an estimate of 
glucose uptake in peripheral tissues. 
 
Central leptin in a hyperinsulinemic euglycemic pancreatic clamp setup dose 
dependently favored gluconeogenesis over glycogenolysis in earlier studies, 
but did not affect overall hGP (Liu et al. 1998). This observed decrease in 
hGP could be due to suppressed gluconeogenesis, which could also explain 
elevated levels of TCA cycle intermediates. 
 
Conclusion, Implications for the pathogenesis of diabetes mellitus and 
possible treatment options  
The ability of central leptin to suppress hepatic glucose production in insulin 
sensitive rats supports the role of hypothalamic control of glucose 
homeostasis. Interestingly several studies (Brown and Goldstein 2008) 
showed that hepatic insulin resistance only affected glucose metabolism, 
while de-novo lipogenesis increased due to hyperinsulinemia. Our study 
shows that MBH leptin or insulin does not affect key enzymes involved in de-
novo lipogenesis, but MBH leptin in turn is able to increase hepatic insulin 
sensitivity to suppress hGP, supported by earlier studies (Pocai et al. 2005b) 
demonstrating improved insulin sensitivity through central leptin 
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administration in a model of induced insulin resistance (caused by a brief 
period of high fat feeding). 
While centrally administered leptin or insulin would be unfeasible in a clinical 
setup, earlier studies investigated intranasal application of insulin (Benedict et 
al. 2008, Born et al. 2002, Hallschmid et al. 2012) and showed clinical benefit 
by reducing calorie intake in men or increasing postprandial satiety in women 
without reducing overall calorie intake. Studies investigating intranasal leptin 
recently showed a significant reduction of appetite and weight in a rodent 
model (Schulz et al. 2012). Further clinical studies involving intranasal 
application of either insulin or leptin are therefore a promising option for 
additional treatment of obesity or DM2, as managing blood glucose levels 
today is still understood as the single most important, yet challenging (Ahola 
and Groop 2012) step in treatment of DM. 
 
With regard to fatty acid metabolism and TCA cycle anaplerosis, we found 
implications for suppressed long chain fatty acid β-oxidation and favoring of 
carbohydrate and amino acid utilization in oxidative phosphorylation. As MBH 
insulin has been shown to suppress lipolysis in WAT (Scherer et al. 2011), 
MBH leptin is known to induce lipolysis in WAT (Buettner et al. 2008). While 
our glycerol tracer analysis support a decrease of systemic lipolysis through 
MBH insulin, no change could be seen for MBH leptin indicating that an 
increase in lipolysis in visceral WAT may be counter regulated through an 
increase in fatty acid and glycerol metabolism/utilization which leptin is known 
to induce (Park et al. 2006). Although systemic NEFA levels remained 
unchanged in both leptin and insulin MBH infused animals, FFA levels in the 
portal vein might be decreased or increased respectively, as elevated NEFA 
levels have been shown to increase gluconeogenesis and glycogenolysis in a 
hyperglycemic state (Kehlenbrink et al. 2012). Therefore a decrease of 
lipolysis by MBH insulin might in part be responsible for MBH insulin’s ability 
to suppress hGP (Scherer et al. 2011). 
 
Central leptin and insulin largely regulate WAT metabolism through the 
sympathetic nervous system. If central leptin and insulin only affected hepatic 
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metabolism through this system, one would expect opposing effects on 
hepatic metabolism. Yet most changes seen in liver samples are similar in 
both treatment groups, suggestive of alternative signaling pathways, including 
but not limited to the parasympathetic nervous system (Li et al. 2011).  
Nonetheless decrease in fatty acid β-oxidation without increase of systemic 
fatty acids or triglycerides raise the clinically relevant question if increased 
hypothalamic levels of either leptin or insulin abet the development of 
steatosis hepatis (Satapati et al. 2012, Sunny et al. 2011), although studies 
investigating chronic ICV leptin infusion found hepatic triglycerides to actually 
be decreased (Warne et al. 2011). 
 
Our work demonstrates that both insulin and leptin alter hepatic energy 
metabolism. We find that insulin and leptin alter branched-chain amino acid 
(BCAA) levels in blood plasma. Earlier studies have suggested that increased 
BCAAs are associated with insulin resistance (Newgard et al. 2009, Newgard 
2012, Shah et al. 2012) or might even serve as novel biomarkers to evaluate 
risk of DM (Lu et al. 2013a, McCormack et al. 2013). Elevated BCAAs could 
either be due to increased protein intake that is commonly seen in a western 
diet, or through metabolism of protein (Tai et al. 2010). Consistent with our 
observations of decreased plasma BCAAs is the notion that insulin is an 
anabolic hormone that suppresses proteolysis and lipolysis (Burns et al. 1979, 
Goldberg 1979); and although leptin is not understood to be an anabolic 
hormone, it is able to preserve lean body mass while reducing fat mass and 
therefore has anabolic properties (Halaas et al. 1995).  
 
Our work therefore identifies numerous pathways affected by central leptin 
and insulin. Further studies are needed  to examine the exact mechanisms 









Group size and the use of an animal model 
One limiting factor in our study was probably the small group size of 4 animals 
(3-4 for MBH aCSF) in the stable-isotope tracer group. Since metabolomics 
and pancreatic clamps are very expensive and time-consuming we were not 
able to perform additional metabolomic analysis to increase the group size. 
Furthermore, our repeated clamps in turn did clearly show the effect we 
anticipated, despite their relatively small group size.  
 
An animal model often serves as a substitute for studies in humans, because 
of the feasibility and fewer genetic variables of inbred animals. In addition, 
animal care guidelines recommend the use of the smallest animals sufficient 
to conduct a study, which in our case resulted in a rat model. While we could 
have used mice instead, the recovery rate of rats after surgery and the 
accuracy of correctly placed MBH cannulae were markedly improved when 
using rats instead of mice.  
The discrepancy in metabolic pathways between rats and humans might 






Background: While hepatic insulin resistance arises as one of the earliest 
causes of impaired glucose tolerance (IGT) and diabetes mellitus type 2 
(DM2), the metabolic pathways involved are still poorly understood. In recent 
years the hypothalamus has been demonstrated to regulate whole body 
glucose and lipid metabolism and therefore DM2 and IGT. In an unbiased 
non-hypothesis driven approach our study aimed to further dissect the 
metabolic pathways affected by hypothalamic insulin and leptin signaling. 
Methods: In order to investigate the role of leptin and insulin signaling in the 
hypothalamus, we infused leptin or insulin into the mediobasal Hypothalamus 
(MBH) of male Sprague-Dawley rats and measured glucose production, 
glucose uptake via tracer-dilution technique under euglycemic pancreatic 
clamp conditions. Western blots, enzyme linked assays and mass 
spectrometry, were used to simultaneously analyse multiple metabolic 
pathways. 
Results: MBH leptin and insulin have similar effects on hepatic energy 
metabolism (figure 16). Targeted metabolomics analysis revealed (via 
measurement of acylcarnitines) that central insulin and leptin suppress long 
chain fatty acid β-oxidation in the liver and lead to increased levels of several 
TCA cycle intermediates (figure 16) as well as decreased branched-chain 
amino acids (BCAAs) in blood plasma. 
Conclusion: The actions of leptin and insulin in the MBH increased 
gluconeogenic substrate breakdown in the liver through a decrease in fatty 
acid B-oxidation and an increase of oxidative phosphorylation of amino acid 
and glucose metabolites. Moreover, central leptin and insulin improved insulin 
sensitivity and the metabolic profile through reductions in plasma levels of 

















































































Figure 16: Illustration of selected metabolites and their role in shown metabolic pathways. (*P < 
0.05 MBH aCSF vs. MBH Insulin and MBH Leptin; **P < 0.01 aCSF vs. MBH Insulin 
and MBH Leptin, student’s two-tailed unpaired t-Test, n=4). Green shows an  increase 
in metabolite levels in MBH leptin treated animals vs. MBH aCSF, Light blue formatted 
metablites are increased in MBH insulin treated animals vs. MBH aCSF. Red 
indicates a decrease of the metabolite in MBH leptin vs. vehicle. Malonyl-Coa 
increase implicated impaired CPT activity and therefore decreased oxidative 
phosphorylation of fatty acid derived acylcarnitines. The overall increase in TCA cycle 
metabolites, known as anaplerosis, indicated an increased flux through the TCA cycle. 
Mostly metabolites from glucose and gluconeogenic amino acids were increased, 
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